Medtronic raises annual profit forecast on strong demand for heart devices

Medtronic also said it has decided to exit its unprofitable ventilator product line within its patient monitoring and respiratory interventions business.;

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2024-02-22 03:30 GMT | Update On 2024-03-27 07:53 GMT

Toronto: Medical device maker Medtronic on Tuesday raised annual profit forecast for the third time this fiscal, banking on higher demand for its heart and diabetes devices, sending the company's shares up nearly 4 per cent in premarket trading.

Demand for medical devices has picked up pace as non-urgent procedures, which were deferred during the pandemic, recovered in the past year with easing hospital staff shortages and people becoming regular with check-ups.

Medtronic expects adjusted profit for the fiscal 2024 to be between $5.19 and $5.21 per share, compared with its previous forecast range of $5.13 and $5.19 per share.

Sales at the company's heart devices unit, its biggest revenue driver, increased 6.1 per cent to $2.93 billion, versus analysts' estimate of $2.89 billion.

Sales at the diabetes unit were $640 million, also above analysts' estimate of $601.9 million.

Medtronic also said it has decided to exit its unprofitable ventilator product line within its patient monitoring and respiratory interventions (PMRI) business.

CEO Geoff Martha had said in November the company was planning to spin off its PMRI business, which is a part of its medical surgical portfolio, by the first half of the next fiscal year.

Medtronic said on Tuesday it would combine the remaining businesses within PMRI operating units into a single unit.

The company also said these operational changes would eliminate the position of executive vice president and president of medical surgical portfolio, currently held by Robert White. White would leave the company effective April 26.

Medtronic's revenue for the third quarter rose 4.7 per cent to $8.09 billion. Analysts on average estimated $7.95 billion, according to LSEG data.

The company posted adjusted profit of $1.30 per share for the quarter, compared with analysts' estimate of $1.26 per share.

Read also: USFDA approves Medtronic Percept RC Deep Brain Stimulation system

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Medtronic raises annual profit forecast on strong demand for heart devices

Medtronic also said it has decided to exit its unprofitable ventilator product line within its patient monitoring and respiratory interventions business.;

Similar News

Morepen Medipath, Bimedical FZE to form JV company in India

Govt Amends Marketing Code for Medical Devices, Details

ICMR, CDSCO, Industry leaders emphasize collaboration, regulatory reforms to strengthen India's pharma leadership

GE HealthCare Revolution Vibe CT system gets USFDA clearance

India MedTech Expo 2025: DoP to hold second edition from 4th to 6th September

Minister calls for strong focus on RnD to produce affordable, high-quality medical devices

India making major strides towards self reliance in high end medical devices

AiMeD Flags Risks in GST Overhaul For Medical Devices, Seeks Balanced 5%-12% Tax Structure